Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.0924 UNCHANGED
Streaming Delayed Price Updated: 12:58 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn... 
Via Benzinga
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia 
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.   
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage 
Via Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, 
Via Benzinga
Awakn Life Sciences Corp Shares Rally 77% After Earning ILAP Expedited Approval Pathway For Its Ketamine-Assisted AUD Therapeutic ($AWKNF)
Via AB Newswire
Exposures Product Safety
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for... 
Via Benzinga
Awakn Life Sciences Corp Earns Global AUD Treatment Interest With A New Class Of Psychedelics-Based Therapeutic ($AWKNF)
Via AB Newswire
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect 
Via Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month
Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the... 
Via Talk Markets
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: 
Via Benzinga
UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites
Awakn Life Sciences Corp. 
Via Benzinga
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. 
Via Talk Markets
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
Psychedelics biotech Awakn Life Sciences Corp. 
Via Benzinga
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon 
Via Benzinga
Psychedelic Drug Stocks Index Has A Good Week
We track six psychedelic stocks researching the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances. 
Via Talk Markets
A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest
A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic.  
Via Benzinga
Psychedelic Drug Stocks Index Continued To Decline Last Week
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter... 
Via Talk Markets
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup
Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics 
Via Benzinga
EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC
NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring 
Via Benzinga
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats
(Part four of a four-part series - Read part three) 
Via Benzinga
Can Ketamine Treat Alcohol Addiction? The Awakn Approach
(Part three of a four-part series) 
Via Benzinga
Psychedelic Drug Stocks Index Up Slightly This Week
There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD. 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.